Skip to main content

Advertisement

Table 3 GuHCl addition during sample preparation impacts amyloid-β peptide recovery from Alzheimer’s disease cerebrospinal fluid aliquots

From: Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays

 1–42 1–40 1–38 1–37 1–34
GuHCl before transfer GuHCl after transfer GuHCl before transfer GuHCl after transfer GuHCl before transfer GuHCl after transfer GuHCl before transfer GuHCl after transfer GuHCl before transfer GuHCl after transfer
No. of subjects 7 7 7 7 7 7 7 7 5 3
Difference between 0.1-ml and 0.5-ml aliquots (%) 5 90 9 63 9 46 9 48 10 14
SD (%) 8 35 8 26 7 23 7 27 10 10
Range (%) − 6 to 18 48–146 − 5 to 16 27–112 1–23 30–89 0–22 24–95 − 2 to 25 5–25
p Value (0.1 ml vs. 0.5 ml) 0.1103 0.001 0.043 0.002 0.0104 0.0047 0.0428 0.0074 0.1199 0.1368
  1. Abbreviations: Aβ Amyloid-β, AD Alzheimer’s disease, GuHCl Guanidine hydrochloride
  2. p values were calculated by paired t test. Boldface values indicate noteworthy changes concomitant with a p value < 0.05
  3. Difference between 0.1-ml and 0.5-ml aliquots (%) = ([b − a]/[a]) × 100, where:
  4. a = [Aβ1-X] recovered from 0.1-ml aliquots
  5. b = [Aβ1–X] recovered from 0.5-ml aliquots